BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Daoussis D, Liossis SN, Tsamandas AC, Kalogeropoulou C, Kazantzi A, Sirinian C, Karampetsou M, Yiannopoulos G, Andonopoulos AP. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford). 2010;49:271-280. [PMID: 19447770 DOI: 10.1093/rheumatology/kep093] [Cited by in Crossref: 246] [Cited by in F6Publishing: 205] [Article Influence: 20.5] [Reference Citation Analysis]
Number Citing Articles
1 Melissaropoulos K, Liossis SN. Decreased CD22 expression and intracellular signaling aberrations in B cells of patients with systemic sclerosis. Rheumatol Int 2018;38:1225-34. [PMID: 29869007 DOI: 10.1007/s00296-018-4076-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
2 Whitfield ML. Editorial: Plasma and B Cell Gene Signatures: Quantitative Targeting and Monitoring of B Cell-Depleting Therapies in Autoimmune Diseases in the Genomic Era: Editorial. Arthritis & Rheumatology 2014;66:10-4. [DOI: 10.1002/art.38192] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
3 Bagnato G, Harari S. Cellular interactions in the pathogenesis of interstitial lung diseases. Eur Respir Rev 2015;24:102-14. [DOI: 10.1183/09059180.00003214] [Cited by in Crossref: 139] [Cited by in F6Publishing: 126] [Article Influence: 23.2] [Reference Citation Analysis]
4 Silver KC, Silver RM. Management of Systemic-Sclerosis-Associated Interstitial Lung Disease. Rheum Dis Clin North Am 2015;41:439-57. [PMID: 26210128 DOI: 10.1016/j.rdc.2015.04.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
5 Ha YJ, Lee YJ, Kang EH. Lung Involvements in Rheumatic Diseases: Update on the Epidemiology, Pathogenesis, Clinical Features, and Treatment. Biomed Res Int 2018;2018:6930297. [PMID: 29854780 DOI: 10.1155/2018/6930297] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 6.7] [Reference Citation Analysis]
6 Eldoma M, Pope J. The contemporary management of systemic sclerosis. Expert Rev Clin Immunol 2018;14:573-82. [PMID: 29874475 DOI: 10.1080/1744666X.2018.1485490] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
7 Viswanath V, Phiske MM, Gopalani VV. Systemic sclerosis: current concepts in pathogenesis and therapeutic aspects of dermatological manifestations. Indian J Dermatol 2013;58:255-68. [PMID: 23918994 DOI: 10.4103/0019-5154.113930] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
8 Klavdianou K, Liossis SN, Sakkas L, Daoussis D. The role of Dickkopf-1 in joint remodeling and fibrosis: A link connecting spondyloarthropathies and scleroderma? Semin Arthritis Rheum 2017;46:430-8. [PMID: 27670695 DOI: 10.1016/j.semarthrit.2016.08.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
9 Daoussis D, Tsamandas A, Antonopoulos I, Filippopoulou A, Papachristou DJ, Papachristou NI, Andonopoulos AP, Liossis SN. B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis. Arthritis Res Ther 2016;18:118. [PMID: 27208972 DOI: 10.1186/s13075-016-1017-y] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
10 Engel P, Gómez-Puerta JA, Ramos-Casals M, Lozano F, Bosch X. Therapeutic targeting of B cells for rheumatic autoimmune diseases. Pharmacol Rev 2011;63:127-56. [PMID: 21245206 DOI: 10.1124/pr.109.002006] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 7.2] [Reference Citation Analysis]
11 Iudici M, Cuomo G, Vettori S, Bocchino M, Sanduzzi Zamparelli A, Cappabianca S, Valentini G. Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): Efficacy of maintenance immunosuppression in responders and non-responders. Seminars in Arthritis and Rheumatism 2015;44:437-44. [DOI: 10.1016/j.semarthrit.2014.09.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
12 Asano Y, Varga J. Rationally-based therapeutic disease modification in systemic sclerosis: Novel strategies. Semin Cell Dev Biol 2020;101:146-60. [PMID: 31859147 DOI: 10.1016/j.semcdb.2019.12.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
13 Horimoto AMC, Costa IPD. Sobreposição de esclerose sistêmica e artrite reumatoide: uma entidade clínica distinta? Revista Brasileira de Reumatologia 2016;56:287-98. [DOI: 10.1016/j.rbr.2014.12.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
14 Rezaei R, Aslani S, Dashti N, Jamshidi A, Gharibdoost F, Mahmoudi M. Genetic implications in the pathogenesis of systemic sclerosis. Int J Rheum Dis 2018;21:1478-86. [DOI: 10.1111/1756-185x.13344] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Sampaio-barros PD, Zimmermann AF, Souza Müller CD, Lobato Borges CT, Medeiros Freire EA, Maretti GB, Marques Neto JF, Fonseca Salgado MC, da Cunha Sauma MDFL, de Azevedo MNL, Fontenelle S, Kayser C. Recomendações sobre diagnóstico e tratamento da esclerose sistêmica. Revista Brasileira de Reumatologia 2013;53:258-75. [DOI: 10.1590/s0482-50042013000300004] [Cited by in Crossref: 8] [Article Influence: 1.0] [Reference Citation Analysis]
16 Asano Y. The Pathogenesis of Systemic Sclerosis: An Understanding Based on a Common Pathologic Cascade across Multiple Organs and Additional Organ-Specific Pathologies. J Clin Med 2020;9:E2687. [PMID: 32825112 DOI: 10.3390/jcm9092687] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
17 Baron M. Targeted Therapy in Systemic Sclerosis. Rambam Maimonides Med J 2016;7. [PMID: 27824545 DOI: 10.5041/RMMJ.10257] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
18 Castelino FV, Moua T. Detection and Management of Interstitial Lung Diseases Associated With Connective Tissue Diseases. ACR Open Rheumatol 2021;3:295-304. [PMID: 33779080 DOI: 10.1002/acr2.11253] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Tang R, Yu J, Shi Y, Zou P, Zeng Z, Tang B, Wang Y, Ling G, Luo M, Xiao R. Safety and efficacy of Rituximab in systemic sclerosis: A systematic review and meta-analysis. Int Immunopharmacol 2020;83:106389. [PMID: 32172205 DOI: 10.1016/j.intimp.2020.106389] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 14.0] [Reference Citation Analysis]
20 Moazedi-Fuerst FC, Kielhauser SM, Bodo K, Graninger WB. Dosage of rituximab in systemic sclerosis: 2-year results of five cases. Clin Exp Dermatol 2015;40:211-2. [PMID: 25250643 DOI: 10.1111/ced.12450] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
21 Fischer A, Distler J. Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases. Clin Rheumatol 2019;38:2673-81. [PMID: 31423560 DOI: 10.1007/s10067-019-04720-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 8.5] [Reference Citation Analysis]
22 Moazedi-Fuerst FC, Kielhauser SM, Brickmann K, Hermann J, Lutfi A, Meilinger M, Brezinschek HP, Graninger WB. Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases. Results of a lower dosage and shorter interval regimen. Scand J Rheumatol 2014;43:257-8. [PMID: 24611681 DOI: 10.3109/03009742.2013.869617] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
23 Daoussis D, Antonopoulos I, Liossis SN, Yiannopoulos G, Andonopoulos AP. Treatment of systemic sclerosis-associated calcinosis: a case report of rituximab-induced regression of CREST-related calcinosis and review of the literature. Semin Arthritis Rheum 2012;41:822-9. [PMID: 22221908 DOI: 10.1016/j.semarthrit.2011.11.007] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
24 Worrell JC, O'Reilly S. Bi-directional communication: Conversations between fibroblasts and immune cells in systemic sclerosis. J Autoimmun 2020;113:102526. [PMID: 32713676 DOI: 10.1016/j.jaut.2020.102526] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
25 Richeldi L, Varone F, Bergna M, de Andrade J, Falk J, Hallowell R, Jouneau S, Kondoh Y, Morrow L, Randerath W, Strek M, Tabaj G. Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence. Eur Respir Rev 2018;27:180074. [PMID: 30578333 DOI: 10.1183/16000617.0074-2018] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 13.7] [Reference Citation Analysis]
26 Schioppo T, Ingegnoli F. Current perspective on rituximab in rheumatic diseases. Drug Des Devel Ther 2017;11:2891-904. [PMID: 29042750 DOI: 10.2147/DDDT.S139248] [Cited by in Crossref: 46] [Cited by in F6Publishing: 17] [Article Influence: 11.5] [Reference Citation Analysis]
27 Daoussis D, Andonopoulos AP. B cell depletion in scleroderma lung disease: A promising new treatment? World J Rheumatol 2013; 3(2): 9-11 [DOI: 10.5499/wjr.v3.i2.9] [Reference Citation Analysis]
28 Haroon M, McLaughlin P, Henry M, Harney S. Cyclophosphamide-refractory scleroderma-associated interstitial lung disease: remarkable clinical and radiological response to a single course of rituximab combined with high-dose corticosteroids. Ther Adv Respir Dis 2011;5:299-304. [PMID: 21593063 DOI: 10.1177/1753465811407786] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
29 Hinchcliff M, O'Reilly S. Current and Potential New Targets in Systemic Sclerosis Therapy: a New Hope. Curr Rheumatol Rep 2020;22:42. [PMID: 32562016 DOI: 10.1007/s11926-020-00918-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
30 Ntelis K, Solomou EE, Sakkas L, Liossis SN, Daoussis D. The role of platelets in autoimmunity, vasculopathy, and fibrosis: Implications for systemic sclerosis. Semin Arthritis Rheum 2017;47:409-17. [PMID: 28602360 DOI: 10.1016/j.semarthrit.2017.05.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
31 Kumánovics G, Péntek M, Bae S, Opris D, Khanna D, Furst DE, Czirják L. Assessment of skin involvement in systemic sclerosis. Rheumatology (Oxford) 2017;56:v53-66. [PMID: 28992173 DOI: 10.1093/rheumatology/kex202] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
32 Thiebaut M, Launay D, Rivière S, Mahévas T, Bellakhal S, Hachulla E, Fain O, Mekinian A. Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review. Autoimmunity Reviews 2018;17:582-7. [DOI: 10.1016/j.autrev.2017.12.010] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 17.0] [Reference Citation Analysis]
33 Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, Truchetet ME, Braun-Moscovici Y, Iannone F, Novikov PI, Lescoat A, Siegert E, Castellví I, Airó P, Vettori S, De Langhe E, Hachulla E, Erler A, Ananieva L, Krusche M, López-Longo FJ, Distler JHW, Hunzelmann N, Hoffmann-Vold AM, Riccieri V, Hsu VM, Pozzi MR, Ancuta C, Rosato E, Mihai C, Kuwana M, Saketkoo LA, Chizzolini C, Hesselstrand R, Ullman S, Yavuz S, Rednic S, Caimmi C, Bloch-Queyrat C, Allanore Y; for EUSTAR network. Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Ann Rheum Dis 2019;78:979-87. [PMID: 30967395 DOI: 10.1136/annrheumdis-2018-214816] [Cited by in Crossref: 69] [Cited by in F6Publishing: 57] [Article Influence: 34.5] [Reference Citation Analysis]
34 Antin-Ozerkis D, Rubinowitz A, Evans J, Homer RJ, Matthay RA. Interstitial lung disease in the connective tissue diseases. Clin Chest Med 2012;33:123-49. [PMID: 22365251 DOI: 10.1016/j.ccm.2012.01.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
35 Sharp C, Mccabe M, Dodds N, Edey A, Mayers L, Adamali H, Millar AB, Gunawardena H. Rituximab in autoimmune connective tissue disease–associated interstitial lung disease. Rheumatology 2016;55:1318-24. [DOI: 10.1093/rheumatology/kew195] [Cited by in Crossref: 48] [Cited by in F6Publishing: 31] [Article Influence: 9.6] [Reference Citation Analysis]
36 Kaegi C, Wuest B, Schreiner J, Steiner UC, Vultaggio A, Matucci A, Crowley C, Boyman O. Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders. Front Immunol 2019;10:1990. [PMID: 31555262 DOI: 10.3389/fimmu.2019.01990] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 22.5] [Reference Citation Analysis]
37 Joly-Battaglini A, Hammarström C, Stankovic B, Aamodt H, Stjärne J, Brustugun OT, Helland Å, Øynebråten I, Corthay A. Rituximab efficiently depletes B cells in lung tumors and normal lung tissue. F1000Res 2016;5:38. [PMID: 27081474 DOI: 10.12688/f1000research.7599.1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
38 Leask A. Emerging targets for the treatment of scleroderma. Expert Opinion on Emerging Drugs 2012;17:173-9. [DOI: 10.1517/14728214.2012.678833] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
39 Zhu L, Chung MP, Gagne L, Guo HH, Guenther Z, Li S, Jacobs S, Morisset J, Mooney JJ, Raj R, Chung L. Rituximab Versus Mycophenolate in the Treatment of Recalcitrant Connective Tissue Disease-Associated Interstitial Lung Disease. ACR Open Rheumatol 2021;3:3-7. [PMID: 33274857 DOI: 10.1002/acr2.11210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
40 Vacchi C, Sebastiani M, Cassone G, Cerri S, Della Casa G, Salvarani C, Manfredi A. Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review. J Clin Med 2020;9:E407. [PMID: 32028635 DOI: 10.3390/jcm9020407] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
41 Moradzadeh M, Aghaei M, Mehrbakhsh Z, Arab-Bafrani Z, Abdollahi N. Efficacy and safety of rituximab therapy in patients with systemic sclerosis disease (SSc): systematic review and meta-analysis. Clin Rheumatol 2021. [PMID: 33796953 DOI: 10.1007/s10067-021-05698-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Iqbal K, Kelly C. Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review. Ther Adv Musculoskelet Dis 2015;7:247-67. [PMID: 26622326 DOI: 10.1177/1759720X15612250] [Cited by in Crossref: 45] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
43 Almeida I, Faria R, Vita P, Vasconcelos C. Systemic sclerosis refractory disease: from the skin to the heart. Autoimmun Rev 2011;10:693-701. [PMID: 21575745 DOI: 10.1016/j.autrev.2011.04.025] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
44 Keir GJ, Maher TM, Ming D, Abdullah R, de Lauretis A, Wickremasinghe M, Nicholson AG, Hansell DM, Wells AU, Renzoni EA. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology. 2014;19:353-359. [PMID: 24286447 DOI: 10.1111/resp.12214] [Cited by in Crossref: 154] [Cited by in F6Publishing: 121] [Article Influence: 19.3] [Reference Citation Analysis]
45 Yanaba K. Strategy for treatment of fibrosis in systemic sclerosis: Present and future. J Dermatol 2016;43:46-55. [PMID: 26782006 DOI: 10.1111/1346-8138.13026] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
46 Matsushita T, Takehara K. An update on biomarker discovery and use in systemic sclerosis. Expert Review of Molecular Diagnostics 2017;17:823-33. [DOI: 10.1080/14737159.2017.1356722] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
47 Hoffmann-Vold AM, Allanore Y, Bendstrup E, Bruni C, Distler O, Maher TM, Wijsenbeek M, Kreuter M. The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating disease. Respir Res 2020;21:197. [PMID: 32703199 DOI: 10.1186/s12931-020-01459-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
48 Schoenfeld SR, Castelino FV. Interstitial lung disease in scleroderma. Rheum Dis Clin North Am 2015;41:237-48. [PMID: 25836640 DOI: 10.1016/j.rdc.2014.12.005] [Cited by in Crossref: 42] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
49 Paola C, Giuliana F, Giovanni O, Cristian C, Domenico B. Dramatic improvement of anti-SS-A/Ro-associated interstitial lung disease after immunosuppressive treatment. Rheumatol Int 2016;36:1015-21. [PMID: 27021338 DOI: 10.1007/s00296-016-3463-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
50 Blank RB, Nwawka OK, Yusov AA, Gordon JK. Inflammatory arthritis in systemic sclerosis: What to do? Journal of Scleroderma and Related Disorders 2019;4:3-16. [DOI: 10.1177/2397198318779532] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
51 Caldas MMVF, Neto FAB, Azevedo KPM, Pimenta IDSF, Oliveira AKDSG, Piuvezam G. Rituximab in systemic sclerosis: A protocol for systematic review. Medicine (Baltimore) 2019;98:e17110. [PMID: 31567948 DOI: 10.1097/MD.0000000000017110] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
52 Phumethum V, Jamal S, Johnson SR. Biologic therapy for systemic sclerosis: a systematic review. J Rheumatol 2011;38:289-96. [PMID: 21041277 DOI: 10.3899/jrheum.100361] [Cited by in Crossref: 40] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
53 de Lauretis A, Veeraraghavan S, Renzoni E. Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? Chron Respir Dis. 2011;8:53-82. [PMID: 21339375 DOI: 10.1177/1479972310393758] [Cited by in Crossref: 103] [Cited by in F6Publishing: 79] [Article Influence: 10.3] [Reference Citation Analysis]
54 Goswami RP, Ray A, Chatterjee M, Mukherjee A, Sircar G, Ghosh P. Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis. Rheumatology (Oxford) 2021;60:557-67. [PMID: 33164098 DOI: 10.1093/rheumatology/keaa550] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
55 Karakontaki FV, Panselinas ES, Polychronopoulos VS, Tzioufas AG. Targeted therapies in interstitial lung disease secondary to systemic autoimmune rheumatic disease. Current status and future development. Autoimmun Rev 2021;20:102742. [PMID: 33333235 DOI: 10.1016/j.autrev.2020.102742] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
56 Daoussis D, Melissaropoulos K, Sakellaropoulos G, Antonopoulos I, Markatseli TE, Simopoulou T, Georgiou P, Andonopoulos AP, Drosos AA, Sakkas L, Liossis SN. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum 2017;46:625-31. [PMID: 27839742 DOI: 10.1016/j.semarthrit.2016.10.003] [Cited by in Crossref: 102] [Cited by in F6Publishing: 86] [Article Influence: 20.4] [Reference Citation Analysis]
57 Fallet B, Walker UA. Current immunosuppressive and antifibrotic therapies of systemic sclerosis and emerging therapeutic strategies. Expert Rev Clin Pharmacol 2020;13:1203-18. [PMID: 33008265 DOI: 10.1080/17512433.2020.1832466] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Gómez Carrera L, Bonilla Hernan G. Pulmonary Manifestations of Collagen Diseases. Archivos de Bronconeumología (English Edition) 2013;49:249-60. [DOI: 10.1016/j.arbr.2012.11.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
59 Manno R, Boin F. Immunotherapy of systemic sclerosis. Immunotherapy. 2010;2:863-878. [PMID: 21091117 DOI: 10.2217/imt.10.69] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
60 Yasuoka H. Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis. Clin Med Insights Circ Respir Pulm Med 2015;9:97-110. [PMID: 26819563 DOI: 10.4137/CCRPM.S23315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
61 Bosello S, De Luca G, Tolusso B, Lama G, Angelucci C, Sica G, Ferraccioli G. B cells in systemic sclerosis: a possible target for therapy. Autoimmun Rev 2011;10:624-30. [PMID: 21545850 DOI: 10.1016/j.autrev.2011.04.013] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 4.8] [Reference Citation Analysis]
62 Pearson DR, Werth VP, Pappas-Taffer L. Systemic sclerosis: Current concepts of skin and systemic manifestations. Clin Dermatol 2018;36:459-74. [PMID: 30047430 DOI: 10.1016/j.clindermatol.2018.04.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
63 Lota HK, Renzoni EA. Circulating biomarkers of interstitial lung disease in systemic sclerosis. Int J Rheumatol 2012;2012:121439. [PMID: 22988462 DOI: 10.1155/2012/121439] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
64 Beyer C, Distler O, Distler JH. Innovative antifibrotic therapies in systemic sclerosis. Curr Opin Rheumatol 2012;24:274-80. [PMID: 22450392 DOI: 10.1097/BOR.0b013e3283524b9a] [Cited by in Crossref: 43] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
65 Taher TE, Ong VH, Bystrom J, Hillion S, Simon Q, Denton CP, Pers JO, Abraham DJ, Mageed RA. Association of Defective Regulation of Autoreactive Interleukin-6-Producing Transitional B Lymphocytes With Disease in Patients With Systemic Sclerosis. Arthritis Rheumatol 2018;70:450-61. [PMID: 29193892 DOI: 10.1002/art.40390] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
66 Saketkoo LA, Scholand MB, Lammi MR, Russell AM. Patient-reported outcome measures in systemic sclerosis-related interstitial lung disease for clinical practice and clinical trials. J Scleroderma Relat Disord 2020;5:48-60. [PMID: 32455167 DOI: 10.1177/2397198320904178] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
67 Koo SM, Kim SY, Choi SM, Lee HK; Korean Interstitial Lung Diseases Study Group. Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 5. Connective Tissue Disease Associated Interstitial Lung Disease. Tuberc Respir Dis (Seoul) 2019;82:285-97. [PMID: 31172701 DOI: 10.4046/trd.2019.0009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
68 Volkmann ER, Tashkin DP. Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies. Ann Am Thorac Soc 2016;13:2045-56. [PMID: 27560196 DOI: 10.1513/AnnalsATS.201606-426FR] [Cited by in Crossref: 43] [Cited by in F6Publishing: 12] [Article Influence: 10.8] [Reference Citation Analysis]
69 Burt RK, Milanetti F. Hematopoietic stem cell transplantation for systemic sclerosis: history and current status. Curr Opin Rheumatol 2011;23:519-29. [PMID: 21857226 DOI: 10.1097/BOR.0b013e32834aa45f] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
70 Saunders P, Tsipouri V, Keir GJ, Ashby D, Flather MD, Parfrey H, Babalis D, Renzoni EA, Denton CP, Wells AU, Maher TM. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials 2017;18:275. [PMID: 28619061 DOI: 10.1186/s13063-017-2016-2] [Cited by in Crossref: 73] [Cited by in F6Publishing: 59] [Article Influence: 18.3] [Reference Citation Analysis]
71 Jeganathan N, Sathananthan M. Connective Tissue Disease-Related Interstitial Lung Disease: Prevalence, Patterns, Predictors, Prognosis, and Treatment. Lung 2020;198:735-59. [DOI: 10.1007/s00408-020-00383-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
72 Cappelli S, Bellando Randone S, Camiciottoli G, De Paulis A, Guiducci S, Matucci-Cerinic M. Interstitial lung disease in systemic sclerosis: where do we stand? Eur Respir Rev 2015;24:411-9. [PMID: 26324802 DOI: 10.1183/16000617.00002915] [Cited by in Crossref: 56] [Cited by in F6Publishing: 43] [Article Influence: 11.2] [Reference Citation Analysis]
73 Karampitsakos T, Vraka A, Bouros D, Liossis SN, Tzouvelekis A. Biologic Treatments in Interstitial Lung Diseases. Front Med (Lausanne) 2019;6:41. [PMID: 30931306 DOI: 10.3389/fmed.2019.00041] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
74 Lee JS, Fischer A. Current and emerging treatment options for interstitial lung disease in patients with rheumatic disease. Expert Rev Clin Immunol 2016;12:509-20. [PMID: 26752397 DOI: 10.1586/1744666X.2016.1139454] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
75 Melissaropoulos K, Kraniotis P, Bogdanos D, Dimitroulas T, Sakkas L, Daoussis D. Targeting very early systemic sclerosis: a case-based review. Rheumatol Int 2019;39:1961-70. [PMID: 31254002 DOI: 10.1007/s00296-019-04357-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
76 de Bourcy CFA, Dekker CL, Davis MM, Nicolls MR, Quake SR. Dynamics of the human antibody repertoire after B cell depletion in systemic sclerosis. Sci Immunol 2017;2:eaan8289. [PMID: 28963118 DOI: 10.1126/sciimmunol.aan8289] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
77 Bejan-Angoulvant T, Naccache JM, Caille A, Borie R, Nunes H, Ferreira M, Cadranel J, Crestani B, Cottin V, Marchand-Adam S; OrphaLung. Evaluation of efficacy and safety of rituximab in combination with mycophenolate mofetil in patients with nonspecific interstitial pneumonia non-responding to a first-line immunosuppressive treatment (EVER-ILD): A double-blind placebo-controlled randomized trial. Respir Med Res 2020;78:100770. [PMID: 32777737 DOI: 10.1016/j.resmer.2020.100770] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Xing NS, Fan GZ, Yan F, Liu YP, Zhang R. Safety and efficacy of rituximab in connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis. Int Immunopharmacol 2021;95:107524. [PMID: 33721757 DOI: 10.1016/j.intimp.2021.107524] [Reference Citation Analysis]
79 Vilela VS, Maretti GB, Gama LMDS, Costa CHD, Rufino RL, Levy RA. Rituximab for the therapy of systemic sclerosis: a series of 10 cases in a single center. Revista Brasileira de Reumatologia (English Edition) 2016;56:458-63. [DOI: 10.1016/j.rbre.2016.06.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
80 Lee JJ, Pope JE. Diagnosis and Management of Systemic Sclerosis: A Practical Approach. Drugs 2016;76:203-13. [PMID: 26659258 DOI: 10.1007/s40265-015-0491-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
81 Daoussis D, Tsamandas AC, Liossis SN, Antonopoulos I, Karatza E, Yiannopoulos G, Andonopoulos AP. B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin. Arthritis Res Ther. 2012;14:R145. [PMID: 22697462 DOI: 10.1186/ar3879] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
82 Clarke JT, Werth VP. Rheumatic manifestations of skin disease. Curr Opin Rheumatol 2010;22:78-84. [PMID: 19851110 DOI: 10.1097/BOR.0b013e328333b9e2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 1.1] [Reference Citation Analysis]
83 Sakkas LI, Bogdanos DP. Systemic sclerosis: New evidence re-enforces the role of B cells. Autoimmun Rev 2016;15:155-61. [PMID: 26497107 DOI: 10.1016/j.autrev.2015.10.005] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 10.2] [Reference Citation Analysis]
84 Chen J, Chi S, Li F, Yang J, Cho WC, Liu X. Biologics-induced interstitial lung diseases in rheumatic patients: facts and controversies. Expert Opin Biol Ther 2017;17:265-83. [PMID: 28117616 DOI: 10.1080/14712598.2017.1287169] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
85 Ntelis K, Gkizas V, Filippopoulou A, Davlouros P, Alexopoulos D, Andonopoulos AP, Daoussis D. Clopidogrel treatment may associate with worsening of endothelial function and development of new digital ulcers in patients with systemic sclerosis: results from an open label, proof of concept study. BMC Musculoskelet Disord 2016;17:213. [PMID: 27188755 DOI: 10.1186/s12891-016-1072-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
86 Sharp C, Dodds N, Mayers L, Millar A, Gunawardena H, Adamali H. The role of biologics in treatment of connective tissue disease-associated interstitial lung disease. QJM 2015;108:683-8. [DOI: 10.1093/qjmed/hcv007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
87 William BM, Harbert T, Ganti AK, Bierman PJ. Small lymphocytic lymphoma in a patient with CREST syndrome. Hematol Oncol Stem Cell Ther 2011;4:132-5. [PMID: 21982887 DOI: 10.5144/1658-3876.2011.132] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
88 Hasegawa M, Takehara K. Potential immunologic targets for treating fibrosis in systemic sclerosis: a review focused on leukocytes and cytokines. Semin Arthritis Rheum 2012;42:281-96. [PMID: 22542279 DOI: 10.1016/j.semarthrit.2012.03.014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
89 Odaka M, Hasegawa M, Hamaguchi Y, Ishiura N, Kumada S, Matsushita T, Komura K, Sato S, Takehara K, Fujimoto M. Autoantibody-mediated regulation of B cell responses by functional anti-CD22 autoantibodies in patients with systemic sclerosis. Clin Exp Immunol 2010;159:176-84. [PMID: 19919568 DOI: 10.1111/j.1365-2249.2009.04059.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
90 Simms RW, Lafyatis R. Rituximab: a potential therapeutic advance in scleroderma: what is the evidence? Rheumatology (Oxford) 2010;49:201-2. [PMID: 20032221 DOI: 10.1093/rheumatology/kep421] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
91 Daoussis D, Andonopoulos AP. Rituximab in the treatment of systemic sclerosis-associated interstitial lung disease: comment on the article by Yoo. Rheumatol Int 2011;31:841-2. [PMID: 20376665 DOI: 10.1007/s00296-010-1485-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
92 Wells AU, Kokosi M, Karagiannis K. Treatment strategies for idiopathic interstitial pneumonias: . Current Opinion in Pulmonary Medicine 2014;20:442-8. [DOI: 10.1097/mcp.0000000000000085] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
93 Smith V, Piette Y, van Praet JT, Decuman S, Deschepper E, Elewaut D, De Keyser F. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol. 2013;40:52-57. [PMID: 23118116 DOI: 10.3899/jrheum.120778] [Cited by in Crossref: 65] [Cited by in F6Publishing: 51] [Article Influence: 7.2] [Reference Citation Analysis]
94 Erre GL, Sebastiani M, Fenu MA, Zinellu A, Floris A, Cavagna L, Renzoni E, Manfredi A, Passiu G, Woodman RJ, Mangoni AA. Efficacy, Safety, and Tolerability of Treatments for Systemic Sclerosis-Related Interstitial Lung Disease: A Systematic Review and Network Meta-Analysis. J Clin Med 2020;9:E2560. [PMID: 32784580 DOI: 10.3390/jcm9082560] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
95 Del Papa N, Zaccara E. From mechanisms of action to therapeutic application: A review on current therapeutic approaches and future directions in systemic sclerosis. Best Pract Res Clin Rheumatol 2015;29:756-69. [PMID: 27107511 DOI: 10.1016/j.berh.2016.02.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
96 Sakkas LI, Tronzas P. The Greek (Hellenic) rheumatology over the years: from ancient to modern times. Rheumatol Int 2019;39:947-55. [PMID: 30805680 DOI: 10.1007/s00296-019-04261-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
97 George PM, Wells AU. Disease staging and sub setting of interstitial lung disease associated with systemic sclerosis: impact on therapy. Expert Review of Clinical Immunology 2018;14:127-35. [DOI: 10.1080/1744666x.2018.1427064] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
98 Becker M, Müller-ladner U, Riemekasten G. Implementation von Leitlinien für eine Therapie der systemischen Sklerose (Sklerodermie): Wunsch und Wirklichkeit. Z Rheumatol 2010;69:310-7. [DOI: 10.1007/s00393-009-0523-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
99 McMahan ZH, Wigley FM. Novel investigational agents for the treatment of scleroderma. Expert Opin Investig Drugs 2014;23:183-98. [PMID: 24261610 DOI: 10.1517/13543784.2014.848852] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
100 Wells AU, Margaritopoulos GA, Antoniou KM, Nicholson AG. Interstitial Lung Disease in Systemic Sclerosis. In: Cottin V, Cordier J, Richeldi L, editors. Orphan Lung Diseases. London: Springer; 2015. pp. 379-90. [DOI: 10.1007/978-1-4471-2401-6_25] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
101 Russell TM, Herzog EL, Bucala R. Flow cytometric identification of fibrocytes in scleroderma lung disease. Methods Mol Biol 2012;900:327-46. [PMID: 22933077 DOI: 10.1007/978-1-60761-720-4_16] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
102 Homer RJ, Herzog EL. Recent advances in pulmonary fibrosis: implications for scleroderma. Curr Opin Rheumatol 2010;22:683-9. [PMID: 20693906 DOI: 10.1097/BOR.0b013e32833ddcc9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
103 Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, Distler O. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74:1188-1194. [PMID: 24442885 DOI: 10.1136/annrheumdis-2013-204522] [Cited by in Crossref: 226] [Cited by in F6Publishing: 192] [Article Influence: 32.3] [Reference Citation Analysis]
104 Aringer M, Denton CP. Systemic sclerosis phase III clinical trials: Hope on the horizon? Journal of Scleroderma and Related Disorders 2018;3:193-200. [DOI: 10.1177/2397198318775353] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
105 Duarte AC, Santos MJ, Cordeiro A. Anti-fibrotic nintedanib—a new opportunity for systemic sclerosis patients? Clin Rheumatol 2018;37:1123-7. [DOI: 10.1007/s10067-017-3867-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
106 Khanna D, Tashkin DP, Denton CP, Lubell MW, Vazquez-Mateo C, Wax S. Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease. Rheumatology (Oxford) 2019;58:567-79. [PMID: 29893938 DOI: 10.1093/rheumatology/key151] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 32.0] [Reference Citation Analysis]
107 Hughes M, Denton CP, Khanna D. Rituximab for the treatment of systemic sclerosis-interstitial lung disease. Rheumatology (Oxford) 2021;60:489-91. [PMID: 33244601 DOI: 10.1093/rheumatology/keaa675] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
108 Maher TM, Wuyts W. Management of Fibrosing Interstitial Lung Diseases. Adv Ther 2019;36:1518-31. [PMID: 31119691 DOI: 10.1007/s12325-019-00992-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
109 van Laar JM. B-cell depletion with rituximab: a promising treatment for diffuse cutaneous systemic sclerosis. Arthritis Res Ther 2010;12:112. [PMID: 20441607 DOI: 10.1186/ar2977] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
110 Herzog EL, Mathur A, Tager AM, Feghali-Bostwick C, Schneider F, Varga J. Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct? Arthritis Rheumatol 2014;66:1967-78. [PMID: 24838199 DOI: 10.1002/art.38702] [Cited by in Crossref: 104] [Cited by in F6Publishing: 96] [Article Influence: 14.9] [Reference Citation Analysis]
111 Eckes B, Moinzadeh P, Sengle G, Hunzelmann N, Krieg T. Molecular and cellular basis of scleroderma. J Mol Med 2014;92:913-24. [DOI: 10.1007/s00109-014-1190-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.7] [Reference Citation Analysis]
112 Becker MO. [Systemic sclerosis : What is currently available for treatment?]. Internist (Berl) 2016;57:1155-63. [PMID: 27796473 DOI: 10.1007/s00108-016-0148-1] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
113 van Laar JM, Simms RW. Immunomodulatory, Immunoablative, and Biologic Therapies. In: Varga J, Denton CP, Wigley FM, Allanore Y, Kuwana M, editors. Scleroderma. Cham: Springer International Publishing; 2017. pp. 567-82. [DOI: 10.1007/978-3-319-31407-5_41] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
114 Mcqueen FM, Solanki K. Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today? Rheumatology 2015;54:757-67. [DOI: 10.1093/rheumatology/keu463] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
115 Cappelli S, Bellando-Randone S, Guiducci S, Matucci-Cerinic M. Is immunosuppressive therapy the anchor treatment to achieve remission in systemic sclerosis? Rheumatology (Oxford) 2014;53:975-87. [PMID: 24185765 DOI: 10.1093/rheumatology/ket312] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
116 Lota HK, Wells AU. The evolving pharmacotherapy of pulmonary fibrosis. Expert Opinion on Pharmacotherapy 2012;14:79-89. [DOI: 10.1517/14656566.2013.758250] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
117 Srikakulapu P, McNamara CA. B cells and atherosclerosis. Am J Physiol Heart Circ Physiol 2017;312:H1060-7. [PMID: 28314764 DOI: 10.1152/ajpheart.00859.2016] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
118 Katsiari CG, Simopoulou T, Alexiou I, Sakkas LI. Immunotherapy of systemic sclerosis. Hum Vaccin Immunother 2018;14:2559-67. [PMID: 29985736 DOI: 10.1080/21645515.2018.1491508] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
119 Vacchi C, Manfredi A, Cassone G, Erre GL, Salvarani C, Sebastiani M. Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease. Drugs Context 2021;10:2020-8-7. [PMID: 33505478 DOI: 10.7573/dic.2020-8-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Volkmann ER, Chung A, Tashkin DP. Managing Systemic Sclerosis-Related Interstitial Lung Disease in the Modern Treatment Era. Journal of Scleroderma and Related Disorders 2017;2:72-83. [DOI: 10.5301/jsrd.5000237] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 4.8] [Reference Citation Analysis]
121 Kobayashi A, Okamoto H. Treatment of interstitial lung diseases associated with connective tissue diseases. Expert Rev Clin Pharmacol 2012;5:219-27. [PMID: 22390563 DOI: 10.1586/ecp.12.9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
122 Vicente-Rabaneda EF, Serra López-Matencio JM, Ancochea J, Blanco R, González-Gay MÁ, Castañeda S. Efficacy and safety of biological drugs in interstitial lung disease associated with connective tissue diseases. Expert Opin Drug Saf 2021;:1-23. [PMID: 34433372 DOI: 10.1080/14740338.2021.1973428] [Reference Citation Analysis]
123 Hachulla E, Agard C, Allanore Y, Avouac J, Bader-Meunier B, Belot A, Berezne A, Bouthors AS, Condette-Wojtasik G, Constans J, De Groote P, Diot E, Dumas F, Jego P, Joly F, Launay D, Le Guern V, Le Quintrec JS, Lescaille G, Meune C, Moulin B, Nguyen C, Omeish N, Pene F, Richard MA, Rochefort J, Roren A, Sitbon O, Sobanski V, Truchetet ME, Mouthon L; Collaborators. French recommendations for the management of systemic sclerosis. Orphanet J Rare Dis 2021;16:322. [PMID: 34304732 DOI: 10.1186/s13023-021-01844-y] [Reference Citation Analysis]
124 Bellan M, Patrucco F, Barone-adesi F, Gavelli F, Castello LM, Nerviani A, Andreoli L, Cavagna L, Pirisi M, Sainaghi PP. Targeting CD20 in the treatment of interstitial lung diseases related to connective tissue diseases: A systematic review. Autoimmunity Reviews 2020;19:102453. [DOI: 10.1016/j.autrev.2019.102453] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 15.0] [Reference Citation Analysis]
125 Schiopu E, Chatterjee S, Hsu V, Flor A, Cimbora D, Patra K, Yao W, Li J, Streicher K, McKeever K, White B, Katz E, Drappa J, Sweeny S, Herbst R. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study. Arthritis Res Ther 2016;18:131. [PMID: 27267753 DOI: 10.1186/s13075-016-1021-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
126 Yoshizaki A. Pathogenic roles of B lymphocytes in systemic sclerosis. Immunol Lett 2018;195:76-82. [PMID: 29307688 DOI: 10.1016/j.imlet.2018.01.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 8.7] [Reference Citation Analysis]
127 Bosello S, Angelucci C, Lama G, Alivernini S, Proietti G, Tolusso B, Sica G, Gremese E, Ferraccioli G. Characterization of inflammatory cell infiltrate of scleroderma skin: B cells and skin score progression. Arthritis Res Ther 2018;20:75. [PMID: 29669578 DOI: 10.1186/s13075-018-1569-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
128 Kafaja S, Clements P. Management of Widespread Skin Thickening in Diffuse Systemic Sclerosis. Curr Treatm Opt Rheumatol 2016;2:49-60. [PMID: 27330933 DOI: 10.1007/s40674-016-0040-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
129 Mehra S, Walker J, Patterson K, Fritzler MJ. Autoantibodies in systemic sclerosis. Autoimmunity Reviews 2013;12:340-54. [DOI: 10.1016/j.autrev.2012.05.011] [Cited by in Crossref: 131] [Cited by in F6Publishing: 114] [Article Influence: 16.4] [Reference Citation Analysis]
130 Misra DP, Ahmed S, Agarwal V. Is biological therapy in systemic sclerosis the answer? Rheumatol Int 2020;40:679-94. [PMID: 31960079 DOI: 10.1007/s00296-020-04515-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
131 Bosello SL, De Luca G, Rucco M, Berardi G, Falcione M, Danza FM, Pirronti T, Ferraccioli G. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum 2015;44:428-36. [PMID: 25300701 DOI: 10.1016/j.semarthrit.2014.09.002] [Cited by in Crossref: 92] [Cited by in F6Publishing: 84] [Article Influence: 13.1] [Reference Citation Analysis]
132 Gibson CD, Kugler MC, Deshwal H, Munger JS, Condos R. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease. Lung 2020;198:597-608. [PMID: 32591895 DOI: 10.1007/s00408-020-00370-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
133 Ntelis K, Bogdanos D, Dimitroulas T, Sakkas L, Daoussis D. Platelets in Systemic Sclerosis: the Missing Link Connecting Vasculopathy, Autoimmunity, and Fibrosis? Curr Rheumatol Rep 2019;21:15. [PMID: 30830444 DOI: 10.1007/s11926-019-0815-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
134 Avouac J, Clements PJ, Khanna D, Furst DE, Allanore Y. Articular involvement in systemic sclerosis. Rheumatology 2012;51:1347-56. [DOI: 10.1093/rheumatology/kes041] [Cited by in Crossref: 52] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
135 Rath E, Zwerina J, Oppl B, Nell-duxneuner V. Efficacy and safety of rituximab in rheumatic diseases. Wien Med Wochenschr 2015;165:28-35. [DOI: 10.1007/s10354-014-0331-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
136 Bruni C, Furst DE. The burning question: To use or not to use cyclophosphamide in systemic sclerosis. Eur J Rheumatol 2020;7:S237-41. [PMID: 33164737 DOI: 10.5152/eurjrheum.2020.19104] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
137 Perelas A, Arrossi AV, Highland KB. Pulmonary Manifestations of Systemic Sclerosis and Mixed Connective Tissue Disease. Clin Chest Med 2019;40:501-18. [PMID: 31376887 DOI: 10.1016/j.ccm.2019.05.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
138 Constantin T, Foeldvari I, Pain CE, Pálinkás A, Höger P, Moll M, Nemkova D, Weibel L, Laczkovszki M, Clements P, Torok KS. Development of minimum standards of care for juvenile localized scleroderma. Eur J Pediatr 2018;177:961-77. [DOI: 10.1007/s00431-018-3144-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 9.3] [Reference Citation Analysis]
139 Giuggioli D, Lumetti F, Colaci M, Fallahi P, Antonelli A, Ferri C. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Autoimmunity Reviews 2015;14:1072-8. [DOI: 10.1016/j.autrev.2015.07.008] [Cited by in Crossref: 90] [Cited by in F6Publishing: 80] [Article Influence: 15.0] [Reference Citation Analysis]
140 Pendergrass SA, Lemaire R, Francis IP, Mahoney JM, Lafyatis R, Whitfield ML. Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies. J Invest Dermatol 2012;132:1363-73. [PMID: 22318389 DOI: 10.1038/jid.2011.472] [Cited by in Crossref: 98] [Cited by in F6Publishing: 93] [Article Influence: 10.9] [Reference Citation Analysis]
141 Balbir-Gurman A, Braun-Moscovici Y. Scleroderma - new aspects in pathogenesis and treatment. Best Pract Res Clin Rheumatol 2012;26:13-24. [PMID: 22424190 DOI: 10.1016/j.berh.2012.01.011] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
142 Valeur NS, Stevens AM, Ferguson MR, Effmann EL, Iyer RS. Multimodality thoracic imaging of juvenile systemic sclerosis: emphasis on clinical correlation and high-resolution CT of pulmonary fibrosis. AJR Am J Roentgenol 2015;204:408-22. [PMID: 25615765 DOI: 10.2214/AJR.14.12461] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
143 Fischer A, Patel NM, Volkmann ER. Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention. Open Access Rheumatol 2019;11:283-307. [PMID: 31849543 DOI: 10.2147/OARRR.S226695] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
144 Asano Y, Jinnin M, Kawaguchi Y, Kuwana M, Goto D, Sato S, Takehara K, Hatano M, Fujimoto M, Mugii N, Ihn H. Diagnostic criteria, severity classification and guidelines of systemic sclerosis. J Dermatol 2018;45:633-91. [PMID: 29687465 DOI: 10.1111/1346-8138.14162] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
145 Horimoto AM, da Costa IP. Overlap between systemic sclerosis and rheumatoid arthritis: a distinct clinical entity? Rev Bras Reumatol Engl Ed 2016;56:287-98. [PMID: 27476621 DOI: 10.1016/j.rbre.2014.12.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
146 Boonstra M, Meijs J, Dorjée AL, Marsan NA, Schouffoer A, Ninaber MK, Quint KD, Bonte-Mineur F, Huizinga TWJ, Scherer HU, de Vries-Bouwstra JK. Rituximab in early systemic sclerosis. RMD Open 2017;3:e000384. [PMID: 28879049 DOI: 10.1136/rmdopen-2016-000384] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
147 Mirsaeidi M, Barletta P, Glassberg MK. Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management. Front Med (Lausanne) 2019;6:248. [PMID: 31737640 DOI: 10.3389/fmed.2019.00248] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
148 Narváez J, LLuch J, Molina-Molina M, Vicens-Zygmunt V, Luburich P, Yañez MA, Nolla JM. Rituximab as a rescue treatment added on mycophenolate mofetil background therapy in progressive systemic sclerosis associated interstitial lung disease unresponsive to conventional immunosuppression. Semin Arthritis Rheum 2020;50:977-87. [PMID: 32911289 DOI: 10.1016/j.semarthrit.2020.08.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
149 Mavropoulos A, Simopoulou T, Varna A, Liaskos C, Katsiari CG, Bogdanos DP, Sakkas LI. Breg Cells Are Numerically Decreased and Functionally Impaired in Patients With Systemic Sclerosis: BREG CELLS IN SYSTEMIC SCLEROSIS. Arthritis & Rheumatology 2016;68:494-504. [DOI: 10.1002/art.39437] [Cited by in Crossref: 74] [Cited by in F6Publishing: 70] [Article Influence: 14.8] [Reference Citation Analysis]
150 Daoussis D, Liossis SN. Treatment of systemic sclerosis associated fibrotic manifestations: Current options and future directions. Mediterr J Rheumatol 2019;30:33-7. [PMID: 32185340 DOI: 10.31138/mjr.30.1.33] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
151 Sakkas LI, Daoussis D, Mavropoulos A, Liossis SN, Bogdanos DP. Regulatory B cells: New players in inflammatory and autoimmune rheumatic diseases. Semin Arthritis Rheum. 2019;48:1133-1141. [PMID: 30409417 DOI: 10.1016/j.semarthrit.2018.10.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
152 Asano Y. Recent advances in the treatment of skin involvement in systemic sclerosis. Inflamm Regen 2017;37:12. [PMID: 29259711 DOI: 10.1186/s41232-017-0047-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
153 Melissaropoulos K, Daoussis D. B cells in systemic sclerosis: from pathophysiology to treatment. Clin Rheumatol 2021;40:2621-31. [PMID: 33745085 DOI: 10.1007/s10067-021-05665-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
154 Morris-Rosenfeld S, Lipinski MJ, McNamara CA. Understanding the role of B cells in atherosclerosis: potential clinical implications. Expert Rev Clin Immunol 2014;10:77-89. [PMID: 24308836 DOI: 10.1586/1744666X.2014.857602] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
155 Ahmed S, Pattanaik SS, Rai MK, Nath A, Agarwal V. Interstitial lung disease in Systemic sclerosis: insights into pathogenesis and evolving therapies. Mediterr J Rheumatol 2018;29:140-7. [PMID: 32185315 DOI: 10.31138/mjr.29.3.140] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
156 Gan Y, Reilkoff R, Peng X, Russell T, Chen Q, Mathai SK, Homer R, Gulati M, Siner J, Elias J, Bucala R, Herzog E. Role of semaphorin 7a signaling in transforming growth factor β1-induced lung fibrosis and scleroderma-related interstitial lung disease. Arthritis Rheum 2011;63:2484-94. [PMID: 21484765 DOI: 10.1002/art.30386] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 5.9] [Reference Citation Analysis]
157 Ebata S, Yoshizaki A, Fukasawa T, Miura S, Takahashi T, Sumida H, Asano Y, Sato S. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease. J Dermatol 2019;46:1006-13. [PMID: 31502326 DOI: 10.1111/1346-8138.15079] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
158 Sircar G, Goswami RP, Sircar D, Ghosh A, Ghosh P. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial. Rheumatology 2018;57:2106-13. [DOI: 10.1093/rheumatology/key213] [Cited by in Crossref: 83] [Cited by in F6Publishing: 60] [Article Influence: 27.7] [Reference Citation Analysis]
159 Bruni C, Praino E, Allanore Y, Distler O, Gabrielli A, Iannone F, Matucci-Cerinic M. Use of biologics and other novel therapies for the treatment of systemic sclerosis. Expert Rev Clin Immunol 2017;13:469-82. [PMID: 27899043 DOI: 10.1080/1744666X.2017.1263153] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 4.6] [Reference Citation Analysis]
160 Zulian F, Dal Pozzolo R, Meneghel A, Castaldi B, Marcolongo R, Caforio ALP, Martini G. Rituximab for rapidly progressive juvenile systemic sclerosis. Rheumatology (Oxford) 2020;59:3793-7. [PMID: 32442284 DOI: 10.1093/rheumatology/keaa193] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
161 Sanges S, Guerrier T, Launay D, Lefèvre G, Labalette M, Forestier A, Sobanski V, Corli J, Hauspie C, Jendoubi M, Yakoub-Agha I, Hatron PY, Hachulla E, Dubucquoi S. Role of B cells in the pathogenesis of systemic sclerosis. Rev Med Interne 2017;38:113-24. [PMID: 27020403 DOI: 10.1016/j.revmed.2016.02.016] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
162 Boin F, Wigley FM. Clinical Features and Treatment of Scleroderma. Kelley's Textbook of Rheumatology. Elsevier; 2013. pp. 1366-1403.e4. [DOI: 10.1016/b978-1-4377-1738-9.00084-0] [Cited by in Crossref: 7] [Article Influence: 0.9] [Reference Citation Analysis]
163 Young A, Khanna D. Systemic sclerosis: commonly asked questions by rheumatologists. J Clin Rheumatol 2015;21:149-55. [PMID: 25807095 DOI: 10.1097/RHU.0000000000000232] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
164 Atienza-Mateo B, Remuzgo-Martínez S, Prieto-Peña D, Mora Cuesta VM, Iturbe-Fernández D, Llorca J, Sánchez-Bilbao L, Corrales A, Blanco Rodríguez G, Gómez-Román JJ, Cifrián JM, González-Gay MÁ. Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center and Literature Review. J Clin Med 2020;9:E3070. [PMID: 32977717 DOI: 10.3390/jcm9103070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
165 Sari A, Guven D, Armagan B, Erden A, Kalyoncu U, Karadag O, Apras Bilgen S, Ertenli I, Kiraz S, Akdogan A. Rituximab Experience in Patients With Long-standing Systemic Sclerosis–Associated Interstitial Lung Disease: A Series of 14 Patients. JCR: Journal of Clinical Rheumatology 2017;23:411-5. [DOI: 10.1097/rhu.0000000000000584] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
166 Wallace B, Vummidi D, Khanna D. Management of connective tissue diseases associated interstitial lung disease: a review of the published literature. Curr Opin Rheumatol 2016;28:236-45. [PMID: 27027811 DOI: 10.1097/BOR.0000000000000270] [Cited by in Crossref: 49] [Cited by in F6Publishing: 25] [Article Influence: 9.8] [Reference Citation Analysis]
167 Lota HK, Keir GJ, Hansell DM, Nicholson AG, Maher TM, Wells AU, Renzoni EA. Novel use of rituximab in hypersensitivity pneumonitis refractory to conventional treatment. Thorax 2013;68:780-1. [DOI: 10.1136/thoraxjnl-2013-203265] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
168 Ferreira M, Borie R, Crestani B, Rigaud P, Wemeau L, Israel-biet D, Leroy S, Quétant S, Plantier L, Dalphin J, Cottin V, Marchand-adam S. Efficacy and safety of rituximab in patients with chronic hypersensitivity pneumonitis (cHP): A retrospective, multicentric, observational study. Respiratory Medicine 2020;172:106146. [DOI: 10.1016/j.rmed.2020.106146] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
169 Castelino FV, Dellaripa PF. Recent progress in systemic sclerosis-interstitial lung disease. Curr Opin Rheumatol 2018;30:570-5. [PMID: 30234724 DOI: 10.1097/BOR.0000000000000544] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
170 Showalter K, Gordon JK. Skin Histology in Systemic Sclerosis: a Relevant Clinical Biomarker. Curr Rheumatol Rep 2020;23:3. [PMID: 33244633 DOI: 10.1007/s11926-020-00970-z] [Reference Citation Analysis]
171 Bussone G, Mouthon L. Interstitial lung disease in systemic sclerosis. Autoimmun Rev 2011;10:248-55. [PMID: 20863911 DOI: 10.1016/j.autrev.2010.09.012] [Cited by in Crossref: 74] [Cited by in F6Publishing: 59] [Article Influence: 6.7] [Reference Citation Analysis]
172 Koo SM, Uh ST. Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist's point of view. Korean J Intern Med 2017;32:600-10. [PMID: 28704913 DOI: 10.3904/kjim.2016.212] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
173 Numajiri H, Yoshizaki A, Ebata S, Fukasawa T, Yamashita T, Takahashi T, Taniguchi T, Asano Y, Sato S. Successful treatment with rituximab in a Japanese patient with systemic sclerosis-associated interstitial lung disease resistant to oral steroid and cyclophosphamide. J Dermatol 2018;45:e140-1. [PMID: 29265579 DOI: 10.1111/1346-8138.14189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
174 Chartrand S, Fischer A. Management of connective tissue disease-associated interstitial lung disease. Rheum Dis Clin North Am 2015;41:279-94. [PMID: 25836643 DOI: 10.1016/j.rdc.2015.01.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
175 de Paula DR, Klem FB, Lorencetti PG, Muller C, Azevedo VF. Rituximab-induced regression of CREST-related calcinosis. Clin Rheumatol 2013;32:281-3. [DOI: 10.1007/s10067-012-2124-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
176 Gómez Carrera L, Bonilla Hernan G. Pulmonary manifestations of collagen diseases. Arch Bronconeumol 2013;49:249-60. [PMID: 23683373 DOI: 10.1016/j.arbres.2012.11.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
177 Daoussis D, Liossis SN. B cells tell scleroderma fibroblasts to produce collagen. Arthritis Res Ther 2013;15:125. [PMID: 24611177 DOI: 10.1186/ar4392] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
178 Kouranos V, Miranda G, Corte TJ, Renzoni EA. New treatment paradigms for connective tissue disease-associated interstitial lung disease. Curr Opin Pulm Med 2018;24:453-60. [PMID: 30020142 DOI: 10.1097/MCP.0000000000000508] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
179 Sung YK, Chung L. Connective tissue disease-associated pulmonary arterial hypertension. Rheum Dis Clin North Am 2015;41:295-313. [PMID: 25836644 DOI: 10.1016/j.rdc.2015.01.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
180 Mendoza FA, Mansoor M, Jimenez SA. Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures Perspectives. Expert Opin Orphan Drugs 2016;4:31-47. [PMID: 27812432 DOI: 10.1517/21678707.2016.1114454] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
181 Vilela VS, Maretti GB, Silva Gama LMD, Costa CHD, Rufino RL, Levy RA. Tratamento da esclerose sistêmica com rituximabe: uma série de 10 casos em centro único. Revista Brasileira de Reumatologia 2016;56:458-63. [DOI: 10.1016/j.rbr.2016.04.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
182 Koutroumpas A, Ziogas A, Alexiou I, Barouta G, Sakkas LI. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol. 2010;29:1167-1168. [PMID: 20532938 DOI: 10.1007/s10067-010-1498-z] [Cited by in Crossref: 49] [Cited by in F6Publishing: 38] [Article Influence: 4.5] [Reference Citation Analysis]
183 Assassi S, Radstake TR, Mayes MD, Martin J. Genetics of scleroderma: implications for personalized medicine? BMC Med 2013;11:9. [PMID: 23311619 DOI: 10.1186/1741-7015-11-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
184 Matsuda KM, Yoshizaki A, Kuzumi A, Fukasawa T, Ebata S, Miura S, Toyama T, Yoshizaki A, Sumida H, Asano Y, Oba K, Sato S. Skin thickness score as a surrogate marker of organ involvements in systemic sclerosis: a retrospective observational study. Arthritis Res Ther 2019;21:129. [PMID: 31138286 DOI: 10.1186/s13075-019-1919-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
185 Hant FN, Herpel LB, Silver RM. Pulmonary manifestations of scleroderma and mixed connective tissue disease.Clin Chest Med. 2010;31:433-449. [PMID: 20692538 DOI: 10.1016/j.ccm.2010.05.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
186 Sumida H, Asano Y, Tamaki Z, Aozasa N, Taniguchi T, Takahashi T, Toyama T, Ichimura Y, Noda S, Akamata K, Miyazaki M, Kuwano Y, Yanaba K, Sato S. Successful experience of rituximab therapy for systemic sclerosis-associated interstitial lung disease with concomitant systemic lupus erythematosus. J Dermatol 2014;41:418-20. [PMID: 24801917 DOI: 10.1111/1346-8138.12461] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
187 Distler O, Volkmann ER, Hoffmann-Vold AM, Maher TM. Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease. Expert Rev Clin Immunol 2019;15:1009-17. [PMID: 31566449 DOI: 10.1080/1744666X.2020.1668269] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
188 Wells AU, Denton CP. Interstitial lung disease in connective tissue disease--mechanisms and management. Nat Rev Rheumatol. 2014;10:728-739. [PMID: 25266451 DOI: 10.1038/nrrheum.2014.149] [Cited by in Crossref: 100] [Cited by in F6Publishing: 78] [Article Influence: 14.3] [Reference Citation Analysis]
189 Ong VH, Denton CP. Innovative therapies for systemic sclerosis. Current Opinion in Rheumatology 2010;22:264-72. [DOI: 10.1097/bor.0b013e328337c3d6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
190 Sakkas LI, Simopoulou T, Katsiari C, Bogdanos D, Chikanza IC. Early systemic sclerosis—opportunities for treatment. Clin Rheumatol 2015;34:1327-31. [DOI: 10.1007/s10067-015-2902-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
191 Koo BS, Hong S, Kim YJ, Kim YG, Lee CK, Yoo B. Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent. Korean J Intern Med 2015;30:104-9. [PMID: 25589842 DOI: 10.3904/kjim.2015.30.1.104] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
192 Solomon JJ, Olson AL, Fischer A, Bull T, Brown KK, Raghu G. Scleroderma lung disease. Eur Respir Rev 2013;22:6-19. [PMID: 23457159 DOI: 10.1183/09059180.00005512] [Cited by in Crossref: 135] [Cited by in F6Publishing: 110] [Article Influence: 16.9] [Reference Citation Analysis]
193 Daoussis D, Liossis SN, Yiannopoulos G, Andonopoulos AP. B-cell depletion therapy in systemic sclerosis: experimental rationale and update on clinical evidence. Int J Rheumatol. 2011;2011:214013. [PMID: 21826145 DOI: 10.1155/2011/214013] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
194 Volkmann ER, Furst DE. Management of Systemic Sclerosis-Related Skin Disease: A Review of Existing and Experimental Therapeutic Approaches. Rheum Dis Clin North Am 2015;41:399-417. [PMID: 26210126 DOI: 10.1016/j.rdc.2015.04.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
195 Cassone G, Sebastiani M, Vacchi C, Erre GL, Salvarani C, Manfredi A. Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review. Drugs Context 2021;10:2020-8-8. [PMID: 33505480 DOI: 10.7573/dic.2020-8-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
196 Perelas A, Silver RM, Arrossi AV, Highland KB. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med 2020;8:304-20. [PMID: 32113575 DOI: 10.1016/S2213-2600(19)30480-1] [Cited by in Crossref: 40] [Cited by in F6Publishing: 16] [Article Influence: 40.0] [Reference Citation Analysis]
197 Topal AA, Dhurat RS. Scleroderma therapy: clinical overview of current trends and future perspective. Rheumatol Int 2013;33:1-18. [PMID: 23011088 DOI: 10.1007/s00296-012-2486-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
198 Schoenfeld SR, Castelino FV. Evaluation and management approaches for scleroderma lung disease. Ther Adv Respir Dis 2017;11:327-40. [PMID: 28621173 DOI: 10.1177/1753465817713680] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
199 Leask A. B cell block: is rituximab a new possible treatment for systemic sclerosis? J Cell Commun Signal 2010;4:201-2. [PMID: 21234128 DOI: 10.1007/s12079-010-0107-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
200 Melsens K, Vandecasteele E, Deschepper E, Badot V, Blockmans D, Brusselle G, De Langhe E, De Pauw M, Debusschere C, Decuman S, Deroo L, Houssiau F, Lenaerts J, Piette Y, Thevissen K, Vanthuyne M, Westhovens R, Wijnant S, De Keyser F, Smith V. Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis. Acta Clinica Belgica 2018;73:119-25. [DOI: 10.1080/17843286.2017.1372244] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
201 Wells AU. Interstitial lung disease in systemic sclerosis. Presse Med. 2014;43:e329-e343. [PMID: 25217474 DOI: 10.1016/j.lpm.2014.08.002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
202 Berghen N, Vulsteke JB, Westhovens R, Lenaerts J, De Langhe E. Rituximab in systemic autoimmune rheumatic diseases: indications and practical use. Acta Clin Belg 2019;74:272-9. [PMID: 30253707 DOI: 10.1080/17843286.2018.1521904] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
203 Bassyouni IH, Azab NA, El-dakrony EM, Fawzi MM, Ghanoum R, Bassyouni RH. Elevated serum levels of a proliferation-inducing ligand in patients with systemic sclerosis: Possible association with myositis? Joint Bone Spine 2011;78:56-61. [DOI: 10.1016/j.jbspin.2010.05.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
204 Das A, Kumar A, Arrossi AV, Ghosh S, Highland KB. Scleroderma-related interstitial lung disease: principles of management. Expert Rev Respir Med 2019;13:357-67. [PMID: 30686069 DOI: 10.1080/17476348.2019.1575732] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
205 Panopoulos ST, Sfikakis PP. Biological treatments and connective tissue disease associated interstitial lung disease. Curr Opin Pulm Med 2011;17:362-7. [PMID: 21597375 DOI: 10.1097/MCP.0b013e3283483ea5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 12] [Article Influence: 4.1] [Reference Citation Analysis]